Here's why the FDA recently approved five new drugs way ahead of schedule.
News & Analysis: BeiGene
BeiGene and Zai Lab offer two ways to invest in what could be a big opportunity.
One of America's largest biotechs will join hands with an industry leader in the rapidly expanding Chinese market.
A short-seller report weighed on the Chinese biotech's shares last month.
China's biopharma gem drifted lower in the first half of 2019, but there's no identifiable explanation or cause for concern.
Technology, drugs, and energy...here are three Chinese stocks from three different industries that you should be watching today.
China's biotech industry is growing quickly, and the innovative BeiGene could be an opportunity in the space.
Shares tumble in response to an industry megamerger.
Whether you're in the U.S. or China, immuno-oncology is one of the hottest areas in biotech right now.
A third-quarter report and a couple of priority reviews from the China Food and Drug Administration encouraged investors.